Lexilium

Bromazepam, the active ingredient in Lexilium, is a benzodiazepine presented as an oral tablet for oral use. It is indicated for the treatment of anxiety disorders and for short‑term relief of anxiety symptoms in adult patients requiring rapid symptom control.

GNH USA supplies Lexilium as a licensed, Good Distribution Practice‑compliant product, providing reliable international sourcing to hospitals, pharmacies and clinics worldwide, with established quality assurance and regulatory support for cross‑border procurement and ensuring timely delivery under applicable import regulations.

Bromazepam is a benzodiazepine that modulates GABA‑A receptors to alleviate anxiety.

- Anxiety disorders: reduction of excessive worry and tension. - Short‑term relief of anxiety symptoms: rapid alleviation of acute anxiety episodes. - Pre‑operative anxiety: calming effect before surgical procedures. - Adjustment disorder with anxiety: helps manage heightened emotional response.

Bromazepam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: reduced motor control and balance. - Memory impairment: difficulty recalling recent events. - Blurred vision: temporary visual disturbances. - Fatigue: generalized lack of energy.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other CNS depressants. - Severe hypotension: marked drop in blood pressure. - Paradoxical reactions: agitation, aggression, or anxiety worsening. - Dependence and withdrawal: risk of physical dependence with prolonged use. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Seizures: rare occurrence during abrupt discontinuation.

Before prescribing or dispensing Bromazepam, clinicians should consider several safety measures.

- Assess renal and hepatic function: adjust use in patients with impairment. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use caution in elderly: increased risk of falls and cognitive impairment. - Avoid concomitant CNS depressants: risk of excessive sedation and respiratory depression. - Evaluate pregnancy and lactation: weigh potential risks against benefits. - Store at room temperature: keep in the original pack, protect from moisture and light.

Bromazepam can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Opioids: additive respiratory depression and profound sedation. - Barbiturates: enhanced CNS depression leading to potentially life‑threatening effects. - Alcohol: severe sedation, impaired coordination, and increased risk of overdose.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase overall sedation. - Antihistamines: enhanced drowsiness and reduced alertness. - CYP3A4 inhibitors (e.g., ketoconazole): can raise bromazepam plasma levels, requiring dose adjustment.